Florentino Villanego

Florentino Villanego

Auto-generated profile, based on publicly available information

Florentino Villanego

Department of Nephrology, Hospital Universitario Puerta del Mar

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Nefrología
Verified
Journal Article
Open access
FVFlorentino Villanego
Florentino Villanego
JNJavier Naranjo
Javier Naranjo
LVLuis Alberto Vigara
Luis Alberto Vigara
JCJuan Manuel Cazorla
Juan Manuel Cazorla
MMMaria Elisa Montero
Maria Elisa Montero
AMAuxiliadora Mazuecos
Auxiliadora Mazuecos
Physical exercise may offer multiple benefits to patients with chronic kidney disease (CKD). However, it was not traditionally recommended because of the possibility of impairing renal function and increasing proteinuria. The objective of this study is to review the clinical trials on physical exercise in patients with CKD and describe its effect on the progression of kidney disease and other factors associated. Randomized clinical trials (RCT) comparing an intervention that included an exercise component with a control group without physical exercise in non-dialysis patients with CKD from 2007 to 2018 in English and Spanish were included. PubMed, Scopus, Embase, Ovid (Medline) and PEDro databases were used for the search. Effects of physical exercise were summarized by the standardized mean difference (SMD). No differences were found in glomerular filtration rate or proteinuria between the intervention group and the control group: SMD -0.3 (P=.81); SMD 26.6 (P=.82). Positive effects were obtained on peak oxygen consumption: SMD 2.5 (P<.001), functional capacity: SMD 56.6 (P<.001), upper limb strength: SMD 6.8 (P<.001) and hemoglobin: SMD 0.3 (P=.003). An improvement on the quality of life was also evident using the KDQOL-36 survey: SMD 3.56 (P=.02) and the SF-36 survey: SMD 6.66 (P=.02). In conclusion, the practice of low-intensity physical exercise routinely has no negative impact on renal function. On the contrary, it improves aerobic and functional capacity, impacting positively on the quality of life.

23 March 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
FVFlorentino Villanego
Florentino Villanego
AMAuxiliadora Mazuecos
Auxiliadora Mazuecos
IPIsabel M. Pérez‐Flores
Isabel M. Pérez‐Flores
FMFrancesc Moreso
Francesc Moreso
AAAmado Andrés
Amado Andrés
TGThe Spanish Society of Nephrology COVID‐19 Group
The Spanish Society of Nephrology COVID‐19 Group
SARS‐CoV‐2 infection has produced high mortality in kidney transplant (KT) recipients, especially in the elderly. Until December‐2020, 1011 KT with COVID‐19 have been prospectively included in the Spanish Registry and followed until recovery or death. In multivariable analysis, age, pneumonia and KT performed ≤6 months before COVID‐19 were predictors of death, whereas gastrointestinal symptoms were protective. Survival analysis showed significant increasing mortality risk in four subgroups according to recipient age and time after KT (age 6 months, age 6 and age ≥65 and time ≤6): mortality rates were, respectively, 11.3%, 24.5%, 35.4% and 54.5% (p<.001). Patients were significantly younger, presented less pneumonia and received less frequently specific anti‐COVID‐19 treatment in the second wave (July‐December) than in the first one (March‐June). Overall mortality was lower in the second wave (15.1 vs. 27.4%, p<.001), but similar in critical patients (66.7% vs. 58.1%, p=.29). The interaction between age and time post‐KT should be considered when selecting recipients for transplantation in the COVID‐19 pandemic. Advanced age and a recent KT should foster strict protective measures, including vaccination.

30 December 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
FVFlorentino Villanego
Florentino Villanego
JCJuan Manuel Cazorla
Juan Manuel Cazorla
LVLuis Alberto Vigara
Luis Alberto Vigara
TGTeresa Garcia
Teresa Garcia
TTTeresa Trujillo
Teresa Trujillo
AMAuxiliadora Mazuecos
Auxiliadora Mazuecos

1 March 2020 in Transplantation Proceedings
Verified
Journal Article
Closed access
JCJuan Manuel Cazorla-López
Juan Manuel Cazorla-López
JWJulie Wu
Julie Wu
FVFlorentino Villanego-Fernández
Florentino Villanego-Fernández
JNJavier Naranjo-Muñoz
Javier Naranjo-Muñoz
LVLuis Alberto Vigara-Sánchez
Luis Alberto Vigara-Sánchez
AMAuxiliadora Mazuecos-Blanca
Auxiliadora Mazuecos-Blanca

28 July 2022 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
FVFlorentino Villanego
Florentino Villanego
AMAuxiliadora Mazuecos
Auxiliadora Mazuecos
BCBeatriz Cubillo
Beatriz Cubillo
MMM José Merino
M José Merino
IPInmaculada Poveda
Inmaculada Poveda
JPJulio Pascual
Julio Pascual
Sotrovimab is a neutralizing monoclonal antibody (mAb) that seems to remain active against recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The evidence on its use in kidney transplant (KT) recipients, however, is limited. We performed a multicenter, retrospective cohort study of 82 KT patients with SARS-CoV-2 infection {coronavirus disease 2019 [COVID-19]} treated with sotrovimab. Median age was 63 years. Diabetes was present in 43.9% of patients, and obesity in 32.9% of patients; 48.8% of patients had an estimated glomerular filtration rate under 30 mL/minute/1.73 m2. Additional anti–COVID-19 therapies were administered to 56 patients, especially intravenous steroids (65.9%). Sotrovimab was administered early (<5 days from the onset of the symptoms) in 46 patients (56%). Early-treated patients showed less likely progression to severe COVID-19 than those treated later, represented as a lower need for ventilator support (2.2% vs 36.1%; P < .001) or intensive care admission (2.2% vs 25%; P = .002) and COVID-19–related mortality (2.2% vs 16.7%; P = .020). In the multivariable analysis, controlling for baseline risk factors to severe COVID-19 in KT recipients, early use of sotrovimab remained as a protective factor for a composite outcome, including need for ventilator support, intensive care, and COVID-19–related mortality. No anaphylactic reactions, acute rejection episodes, impaired kidney function events, or non-kidney side effects related to sotrovimab were observed. Sotrovimab had an excellent safety profile, even in high-comorbidity patients and advanced chronic kidney disease stages. Earlier administration could prevent progression to severe disease, while clinical outcomes were poor in patients treated later. Larger controlled studies enrolling KT recipients are warranted to elucidate the true efficacy of monoclonal antibody therapies.

6 December 2024 in Nefrología (English Edition)
Verified
Journal Article
Open access
LVLuis Alberto Vigara
Luis Alberto Vigara
FVFlorentino Villanego
Florentino Villanego
COCristhian Orellana
Cristhian Orellana
MEMyriam Eady
Myriam Eady
MSMaría Gabriela Sánchez
María Gabriela Sánchez
AMAuxiliadora Mazuecos
Auxiliadora Mazuecos
In kidney transplant (KT) recipients diabetes mellitus (DM) are associated with an increased mortality and a poorer graft survival. Glucagon-like peptide 1 receptor agonists (GLP1-RA) have demonstrated cardiovascular and renal benefits in the general population. However, there is lacking evidence in KT recipients. To analyze the efficacy and safety of glucagon-like peptide 1 receptor GLP1-RA in a cohort of KT recipients. Multicenter retrospective cohort study of KT patients with DM who started subcutaneous GLP1-RA in 3 hospitals in the province of Cádiz between February 2016 and July 2022. Estimated glomerular filtration rate (eGFR), proteinuria, and weight at baseline and after 6 and 12 months were collected. We analyzed glycemic control, blood pressure, lipid profile, and doses and trough levels of tacrolimus. We document episodes of acute rejection (AR), de novo donor-specific antibodies (dnDSA), and adverse effects. During this period, 96 KT with DM started treatment with GLP1-RA, of which 84 had a minimum follow-up of 6 months and 61 were followed for 12 months. A significant reduction was observed in proteinuria (-19.1 mg/g, p = 0.000; -46.6 mg/g, p = 0.000), weight (-3.6 kg, p = 0.000; -3.6 kg, p = 0.000), glycosylated hemoglobin (-0.7%, p = 0.000; -0.9%, p = 0.000), systolic blood pressure (-7.5 mmHg, p = 0.013; -7.3 mmHg, p = 0.004), total cholesterol (-11.5 mg/dL, p = 0.001; -15.6 mg/dl, p = 0.002) and LDL cholesterol (-9.2 mg/dl, p = 0.002; -16.8 mg/dl, p = 0.000) at 6 months and 1 year of follow-up. The eGFR remained stable and the dose and trough levels of tacrolimus did not change. No episodes of AR or development of dnDSA were observed during follow-up. GLP1-RA in KT patients can be a safe and effective option for the management of DM in KT.